摘要
目的观察补气活血汤联合替比夫定(Ld T)治疗HBeAg阳性慢性乙型肝炎(CHB)肝纤维化的临床疗效。方法将128例CHB肝纤维化患者随机分为研究组(68例)和对照组(60例)。对照组单用Ld T(600 mg,每日1次),研究组在对照组基础上,给予补气活血汤,疗程均为24周。比较两组患者治疗前后的肝功能、肝纤四项及HBeAg转阴率。结果治疗24周后,两组肝功能指标均显著下降,且研究组TBi L为(24.1±8.9)μmol/L,低于对照组的(34.7±10.4)μmol/L,差异有统计学意义(P<0.05)。治疗后,两组肝纤维化指标均有所下降,但研究组下降幅度更明显,差异具有统计学意义(P<0.05)。结论补气活血汤联合Ld T在保证抗病毒疗效的同时,还能显著改善CHB肝纤维化患者的TBi L水平及血清肝纤四项指标。
Objective To observe the clinical effect of Buqi Huoxue decoction combined with Telbivudine in treatment of HBeAg-positive related hepatitis B liver fibrosis.Methods 128 patients with CHB liver fibrosis were randomly divided into study group(68 cases)and control group(60 cases).The control group was treated with LdT(600 mg,once a day).The study group was given Buqi Huoxue decoction on the basis of the control group for 24 weeks.The liver function,four liver fibrosis and HBeAg negative rate were compared between the two groups before and after treatment.Results After 24 weeks’treatment,the liver function level of both groups were all declined significantly,while the value of TBiL of the study group was(24.1±8.9)μmol/L,which was lower than(34.7±10.4)μmol/L of the control group,the difference was statistically significant(P<0.05).And the four indexes of hepatic fibrosis of both groups were all reduced after treatment,while the reduction of the study group were more significant,the difference was statistically significant(P<0.05).Conclusion The therapy of Buqi Huoxue decoction combined with telbivudine in treatment of CHB fibrosis can improve the level of TBiL and the serum liver fibrosis indexes,as well as guarantee the antiviral effect.
作者
白志芹
宋会颖
吴瑞卿
高冬
霍红敏
杨晶
陈蜀
安娜
BAI Zhiqin;SONG Huiying;WU Ruiqing;GAO Dong;HUO Hongmin;YANG Jing;CHEN Shu;AN Na(Department of Geriatric Integrated Traditional Chinese and Western Medicine,Qingyuan District People's Hospital in Baoding City,Baoding Hebei 071100,China)
出处
《中国卫生标准管理》
2018年第14期91-94,共4页
China Health Standard Management
